6533b855fe1ef96bd12b0a6c

RESEARCH PRODUCT

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study

Teresa TroianiClaudia Angela Maria FulgenziGiampaolo TortoraGiampaolo TortoraN. ZanalettiAlessandra BoccaccinoEmanuela Dell'aquilaDaniele SantiniP. VitalePasquale LombardiMichele De TursiSusana Rosello KeranenSusana Rosello KeranenFilippo MerloniOlga VendittiMaria Alessandra CalegariAlessandra EmilianiFederica ZorattoFederica MazzucaMarco Maria GermaniDomenico CorsiRiccardo GiampieriSimona Delle MonacheLisa SalvatoreGiampiero PorzioMarisol Huerta AlvaroMichele GhidiniPietro Di MarinoAlessandro ParisiAlice IndiniIna Valeria ZurloPaolo MarchettiDaniele RossiniMario OcchipintiMichela RobertoIngrid GarajováAlessio CortelliniFloriana CamardaKatia CannitaNicola TinariCorrado Ficorella

subject

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerAnti-angiogenicCetuximablcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicinemedicinePanitumumabProgression-free survivalAfliberceptRAS wild-type mCRCPerformance statusCetuximabbusiness.industryPanitumumabanti-angiogenicsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBevacizumabRegimen030104 developmental biologyOncology030220 oncology & carcinogenesissecond-line treatmentbusinessAfliberceptaflibercept; anti-angiogenics; bevacizumab; cetuximab; panitumumab; ras wild-type mcrc; second-line treatmentmedicine.drug

description

: Background: The optimal anti-angiogenic strategy as second-line treatment in RAS wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line treatment is still debated. Methods: This multicenter, real-world, retrospective study is aimed at evaluating the effectiveness of second-line Bevacizumab- and Aflibercept-based treatments after an anti-EGFR based first-line regimen. Clinical outcomes measured were: objective response rate (ORR), progression free survival (PFS), overall survival (OS) and adverse events (AEs) profiles. Results: From February 2011 to October 2019, 277 consecutive mCRC patients received Bevacizumab-based (228, 82.3%) or Aflibercept-based (49, 17.7%) regimen. No significant difference was found regarding ORR. The median follow-up was 27.7 months (95%CI: 24.7&ndash

yearjournalcountryeditionlanguage
2020-05-16Cancers
10.3390/cancers12051259http://dx.doi.org/10.3390/cancers12051259